Global Oncology Academy
Popular
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Komal Jhaveri, MD, FACP
Hiraji Iwata, MD, PhD
- NEW EPISODEMinuteCE®
Breaking New Ground in mCRC: Exploring Novel Targets in mCRC
1.00 program creditScott Kopetz, MD, PhD
Cathy Eng, MD, FACP
- MinuteCE®
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
1.00 program creditKomal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Charles Turck, PharmD, BCPS, BCCCP
David Dingli, MD, PhD
Medical News
- 12/04/2025
- 12/04/2025
- 12/03/2025
- 12/03/2025
CME/CE
Hiraji Iwata, MD, PhD
- MinuteCE®
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
1.00 program creditGiuseppe Curigliano, MD, PhD
- MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
0.50 program creditsJoyce F. Liu, MD, MPH
Kathleen Moore, MD, MS
Clinical Practice
Cynthia Villarreal-Garza, MD, DSc
Giuseppe Curigliano, MD, PhD
Charles Turck, PharmD, BCPS, BCCCP
Brian Mulherin, MD
Charles Turck, PharmD, BCPS, BCCCP
Brian Mulherin, MD
Programs
- MinuteCE®
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
1.00 program creditGiuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Alexandria May, PharmD, BCPS
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
- Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley